Greenblatt D J, Abernethy D R, Boxenbaum H G, Matlis R, Ochs H R, Harmatz J S, Shader R I
Arthritis Rheum. 1986 Aug;29(8):971-80. doi: 10.1002/art.1780290805.
Salicylate kinetics following single, 650-mg intravenous and oral doses of aspirin were evaluated in humans in 2 studies. Complete conversion of aspirin to salicylate was assumed. The first study involved 25 young (25-40 years) and 21 elderly (66-89 years) healthy male and female volunteers. Mean salicylate clearance was lower in elderly females compared with that in young females; however, the difference between young men and elderly men was not significant. Salicylate free fraction in plasma increased significantly with age in men and women. After correction for free fraction, unbound mean clearance was reduced in elderly men compared with young men, and in elderly women compared with young women. Peak plasma salicylate concentrations after taking oral aspirin were not significantly influenced by age, and systemic availability of salicylate in all groups was complete. The second study compared 20 obese subjects (mean weight 113 kg) with 20 normal weight controls (mean weight 67 kg) matched for age, sex, height, and smoking habits. Small differences between obese and control groups were observed in total salicylate volume of distribution (Vd), unbound Vd, and mean clearance of total or unbound salicylate. Following normalization for total weight, however, values of total Vd and mean clearance were significantly smaller in obese subjects than in normal weight subjects. Rate and completeness of salicylate absorption were not influenced by obesity when aspirin was ingested, although peak levels were lower in obese subjects. If applied to multiple doses, the reduced unbound clearance of salicylate in the elderly would imply increased accumulation unless doses are appropriately adjusted downward. During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight.
在两项研究中评估了人类单次静脉注射和口服650毫克阿司匹林后的水杨酸盐动力学。假设阿司匹林完全转化为水杨酸盐。第一项研究涉及25名年轻(25 - 40岁)和21名老年(66 - 89岁)的健康男性和女性志愿者。老年女性的平均水杨酸盐清除率低于年轻女性;然而,年轻男性和老年男性之间的差异不显著。血浆中水杨酸盐的游离分数在男性和女性中均随年龄显著增加。校正游离分数后,老年男性与年轻男性相比,未结合的平均清除率降低,老年女性与年轻女性相比也是如此。口服阿司匹林后血浆水杨酸盐峰值浓度不受年龄显著影响,所有组中水杨酸盐的全身可用性均完全。第二项研究比较了20名肥胖受试者(平均体重113千克)与20名年龄、性别、身高和吸烟习惯相匹配的正常体重对照者(平均体重67千克)。肥胖组和对照组在水杨酸盐的总分布容积(Vd)、未结合Vd以及总水杨酸盐或未结合水杨酸盐的平均清除率方面观察到微小差异。然而,按总体重进行标准化后,肥胖受试者的总Vd值和平均清除率显著低于正常体重受试者。当摄入阿司匹林时,肥胖对水杨酸盐吸收的速率和完全程度没有影响,尽管肥胖受试者的峰值水平较低。如果应用于多剂量,老年人水杨酸盐未结合清除率的降低将意味着积累增加,除非适当向下调整剂量。在长期治疗期间,肥胖个体的水杨酸盐剂量不应按总体重成比例向上调整。